Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)

NCT04716075 is registered in ClinicalTrials.gov with Polish Lymphoma Research Group as lead sponsor.

NCT NCT04716075
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04716075 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)
Lead sponsor
Polish Lymphoma Research Group
Phase
Phase 2
Overall status
Completed
Start date
August 19, 2019
Completion date
July 30, 2024
Enrollment
29 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

adverse event, chronic graft-versus-host-disease, chronic lymphocytic leukemia, mantle cell lymphoma, response rate